INT3803

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1977
Last Reported 2010
Negated 1
Speculated 1
Reported most in Abstract
Documents 45
Total Number 46
Disease Relevance 15.95
Pain Relevance 7.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Igf1) extracellular region (Igf1)
Anatomy Link Frequency
plasma 4
ventral 2
spinal cord 1
skeletal muscle 1
brain 1
Igf1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Clonidine 8 100.00 Very High Very High Very High
Paracetamol 7 99.98 Very High Very High Very High
dexamethasone 135 99.88 Very High Very High Very High
fluoxetine 10 99.78 Very High Very High Very High
Pain 29 99.72 Very High Very High Very High
Hippocampus 13 99.68 Very High Very High Very High
Inflammation 140 99.40 Very High Very High Very High
analgesia 18 99.12 Very High Very High Very High
Somatostatin 25 99.02 Very High Very High Very High
Spinal cord 11 98.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Injury 24 99.92 Very High Very High Very High
Sepsis 87 99.72 Very High Very High Very High
INFLAMMATION 149 99.40 Very High Very High Very High
Targeted Disruption 27 99.26 Very High Very High Very High
Oligospermia 1 99.18 Very High Very High Very High
Apoptosis 19 99.16 Very High Very High Very High
Male Infertility 2 98.78 Very High Very High Very High
Diabetes Mellitus 163 98.44 Very High Very High Very High
Urological Neuroanatomy 23 98.36 Very High Very High Very High
Nociception 23 98.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Repeated, but not acute, FLX treatment decreased IGF-1 mRNA in the hippocampus.
Negative_regulation (decreased) of IGF-1 mRNA in hippocampus associated with hippocampus and fluoxetine
1) Confidence 0.58 Published 2008 Journal Eur Neuropsychopharmacol Section Abstract Doc Link 17961991 Disease Relevance 0.71 Pain Relevance 1.10
If substantiated, then rapid removal of IGF-1 from the brain reported herein may be the reason for the lesser effectiveness of this growth factor.


Negative_regulation (removal) of IGF-1 in brain
2) Confidence 0.56 Published 2005 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1190198 Disease Relevance 0.11 Pain Relevance 0.15
The activity of lanreotide may be due to a reduction in the levels of growth factors such as insulin growth factor 1 (IGF1).
Negative_regulation (reduction) of IGF1
3) Confidence 0.53 Published 1995 Journal Cancer Chemother. Pharmacol. Section Abstract Doc Link 7540120 Disease Relevance 0.57 Pain Relevance 0.10
We report here that the somatostatin analogue octreotide, previously demonstrated to reduce acromegalic levels of IGF-I towards normal, decreased serum IGF-I to 70 +/- 4% (mean +/- SD) of control values and hepatic IGF-I expression to 65 +/- 10% of control values in a short-term non-acromegalic rat model.
Negative_regulation (decreased) of serum IGF-I associated with somatostatin
4) Confidence 0.51 Published 1994 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 8074663 Disease Relevance 0.08 Pain Relevance 0.17
IGF-1 levels decreased after this initial up-regulation, but stayed above 3-fold, whereas TGF- ?
Negative_regulation (decreased) of IGF-1
5) Confidence 0.50 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2688838 Disease Relevance 0.65 Pain Relevance 0
We report here that the somatostatin analogue octreotide, previously demonstrated to reduce acromegalic levels of IGF-I towards normal, decreased serum IGF-I to 70 +/- 4% (mean +/- SD) of control values and hepatic IGF-I expression to 65 +/- 10% of control values in a short-term non-acromegalic rat model.
Negative_regulation (reduce) of IGF-I associated with somatostatin
6) Confidence 0.43 Published 1994 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 8074663 Disease Relevance 0.08 Pain Relevance 0.18
This has led to the proposal that pharmacological reduction of IGF-I bioactivity might represent a novel non-cytotoxic palliative therapy.
Negative_regulation (reduction) of IGF-I associated with palliative
7) Confidence 0.43 Published 1994 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 8074663 Disease Relevance 0.09 Pain Relevance 0.18
The loss of IGF-I support to a population of predominantly nociceptive neurons may contribute to neuropathic pain observed in these models.
Negative_regulation (loss) of IGF-I in neurons associated with nociception and neuropathic pain
8) Confidence 0.43 Published 2002 Journal Neuroreport Section Abstract Doc Link 12352620 Disease Relevance 0.44 Pain Relevance 0.22
The sepsis-induced decrease in hepatic IGF-I mRNA and circulating IGF-I (26%), as well as the 4-fold increase in plasma IGFBP-1 and hepatic IGFBP-1 mRNA were prevented by capsaicin.
Negative_regulation (decrease) of IGF-I in plasma
9) Confidence 0.42 Published 2003 Journal J. Surg. Res. Section Body Doc Link 12888332 Disease Relevance 0.11 Pain Relevance 0
The sepsis-induced decrease in hepatic IGF-I mRNA and circulating IGF-I (26%), as well as the 4-fold increase in plasma IGFBP-1 and hepatic IGFBP-1 mRNA were prevented by capsaicin.
Negative_regulation (decrease) of IGF-I in plasma
10) Confidence 0.42 Published 2003 Journal J. Surg. Res. Section Body Doc Link 12888332 Disease Relevance 0.11 Pain Relevance 0
In contrast, this study found an unexpected delay between the loss of IGF-1 from the CSF-brain-meningeal system and its appearance in blood.
Negative_regulation (loss) of IGF-1 in blood
11) Confidence 0.41 Published 2005 Journal Cerebrospinal Fluid Res Section Body Doc Link PMC1190198 Disease Relevance 0 Pain Relevance 0
IGF-1 deficiency may precipitate the apoptosis of smooth muscle cells migrating to the endothelial layer, as well as the cells found in the media of the vessel.
Negative_regulation (deficiency) of IGF-1 in smooth muscle cells associated with apoptosis
12) Confidence 0.40 Published 2010 Journal Protein J Section Body Doc Link PMC2951508 Disease Relevance 0.36 Pain Relevance 0
For example, very limited mammary epithelial development will take place in the total absence of IGF-I, as demonstrated using the IGF-I-/- mouse model, and administration of 17?
Negative_regulation (using) of IGF-I
13) Confidence 0.40 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC468665 Disease Relevance 0.30 Pain Relevance 0
Bioassayable serum somatomedin (Sm) activity decreased during PTU treatment in one of two experiments but returned to a normal level by recovery day 7.
Negative_regulation (decreased) of somatomedin
14) Confidence 0.39 Published 1977 Journal Endocrinology Section Abstract Doc Link 870309 Disease Relevance 0.22 Pain Relevance 0.09
Tamoxifen reduced serum IGF-I to 74 +/- 12% of control values and hepatic IGF-I expression to 46 +/- 9% of control values in this model, but the combination of octreotide and tamoxifen reduced serum IGF-I concentration to 49 +/- 10% of control values and hepatic IGF-I gene expression to 12 +/- 9% of control values.
Negative_regulation (reduced) of serum IGF-I
15) Confidence 0.37 Published 1994 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 8074663 Disease Relevance 0.06 Pain Relevance 0.15
We recently reported that tamoxifen, a commonly used antiestrogen antineoplastic agent, significantly suppresses IGF-I gene expression and serum IGF-I levels.
Negative_regulation (suppresses) of serum IGF-I
16) Confidence 0.37 Published 1994 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 8074663 Disease Relevance 0.09 Pain Relevance 0.18
Tamoxifen reduced serum IGF-I to 74 +/- 12% of control values and hepatic IGF-I expression to 46 +/- 9% of control values in this model, but the combination of octreotide and tamoxifen reduced serum IGF-I concentration to 49 +/- 10% of control values and hepatic IGF-I gene expression to 12 +/- 9% of control values.
Negative_regulation (reduced) of serum IGF-I
17) Confidence 0.37 Published 1994 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 8074663 Disease Relevance 0.07 Pain Relevance 0.16
IGF-I was reduced in dmCMAP abnormal patients at both test intervals (87.2 ng/ml (65.9 to 119.5) versus 104.5 ng/ml (74.4 to 136.9) and 76.1 ng/ml (55.1 to 119.5) versus 87.2 ng/ml (65.8 to 122)), but differences did not reach statistical significance.
Negative_regulation (reduced) of IGF-I
18) Confidence 0.37 Published 2010 Journal Crit Care Section Body Doc Link PMC2911767 Disease Relevance 0.06 Pain Relevance 0.06
The premise that insulin, IGF-I and IGF-II provide redundant neurotrophic support underlies the following new theory for pathogenesis of diabetic neural disturbances: a loss of insulin activity leads to a secondary partial decline in IGF-I activity.
Spec (partial) Negative_regulation (decline) of IGF-I in neural associated with diabetes mellitus
19) Confidence 0.33 Published 1995 Journal Brain Res. Brain Res. Rev. Section Abstract Doc Link 7711767 Disease Relevance 0.84 Pain Relevance 0.11
Acetaminophen recruits spinal p42/p44 MAPKs and GH/IGF-1 receptors to produce analgesia via the serotonergic system.
Negative_regulation (recruits) of IGF-1 in spinal associated with paracetamol and analgesia
20) Confidence 0.32 Published 2007 Journal Mol. Pharmacol. Section Title Doc Link 17088403 Disease Relevance 0.09 Pain Relevance 1.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox